A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients
about
Heat Shock Protein-Peptide and HSP-Based Immunotherapies for the Treatment of CancerPrognostic and Predictive Value of DAMPs and DAMP-Associated Processes in CancerHigh molecular weight stress proteins: Identification, cloning and utilisation in cancer immunotherapyTherapeutic cancer vaccines: past, present, and futureSystematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanomaHeat shock protein vaccines against glioblastoma: from bench to bedsideA quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trialDendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha.Efficient induction of a Her2-specific anti-tumor response by dendritic cells pulsed with a Hsp70L1-Her2(341-456) fusion protein.Identification of peptide mimotopes of gp96 using single-chain antibody library.Pilot study of intratumoral injection of recombinant heat shock protein 70 in the treatment of malignant brain tumors in childrenA heat shock protein 70-based vaccine with enhanced immunogenicity for clinical use.Trends in cancer immunotherapyTranslating tumor antigens into cancer vaccinesAntitumor activity of mixed heat shock protein/peptide vaccine and cyclophosphamide plus interleukin-12 in mice sarcoma.Vitespen: a preclinical and clinical review.HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future.Dendritic-tumor fusion cells derived heat shock protein70-peptide complex has enhanced immunogenicity.Immunotherapy of cancer in 2012.Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes.Heat shock proteins: pathogenic role in atherosclerosis and potential therapeutic implications.Heat-shock protein-peptide complex-96 for the treatment of cancer.Allogeneic tumor-cell-based vaccines secreting endoplasmic reticulum chaperone gp96.Vaccine therapy for renal cancer.Peptides modulating conformational changes in secreted chaperones: from in silico design to preclinical proof of concept.Peptide-based vaccines for cancer: realizing their potential.Overcoming HBV immune tolerance to eliminate HBsAg-positive hepatocytes via pre-administration of GM-CSF as a novel adjuvant for a hepatitis B vaccine in HBV transgenic miceMyeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma.Dendritic cell-based therapeutic cancer vaccines: what we have and what we need.Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4Multipeptide vaccination in cancer patients.Challenges in clinical design of immunotherapy trials for malignant glioma.Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors.Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?Cancer-associated myeloproliferation: old association, new therapeutic target.The immunological era in melanoma treatment: new challenges for heat shock protein-based vaccine in the advanced disease.Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma: the need for integration for optimal efficacy?A tale of two pities: autologous melanoma vaccines on the brink.Heat-shock proteins as dendritic cell-targeting vaccines--getting warmer.Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases.
P2860
Q26747392-714EE901-7A6C-4D4B-872E-6FBA993B0DE7Q26795466-E58D3016-B282-4167-A8F8-FE85906BCAC5Q26853566-92583CB5-92DD-4C1F-87C6-32E52042B8C3Q26863283-0716E940-EB9B-4DFA-8B57-00A802CEF9BBQ28067023-FD235F7E-31B3-4EE1-AEC5-6626D725BB01Q28087775-96E5C5FD-9E3B-4259-B145-9663A890BC40Q28088679-966FF35E-2580-4EB4-B323-88BD9401819AQ33421740-6F83D037-0CCD-4248-A9F8-F10666667C9BQ33577507-0EB980E8-C4F5-499D-A58D-09CF8CC7FC2FQ33720789-F7E45EE1-EF59-4048-A1BC-B15F15150E33Q33800747-5CAC3D61-D315-4F12-A872-38F5CD66D9FDQ34024513-EDC7EABA-7FDC-4016-9D34-CEBE3F387040Q34052702-D4E4FC64-1682-4C4B-8FD9-A2D00DDB05D2Q34484042-372213D6-1103-4A7E-B724-755910876644Q34668901-73705C43-A9D4-4DED-9A5B-13210E955522Q34996187-D913DE08-CE63-412A-823F-3D7B5C54D6ADQ35009889-9B0050CD-89A6-4CE6-A4C4-8949D7C95C9EQ35592959-F894BFC6-CB9B-42FA-A523-020857BF7FFCQ36243536-2ACA1C1B-A108-4AA6-9751-53DBB873F079Q36419244-3FA5CD1D-2364-40D1-A616-96D045B0D02AQ36488793-569B78AD-7E16-4868-AED6-292D61ED021CQ36909395-717746B1-DB9E-48F3-BDA7-620F70F73AA0Q36981666-02B441E2-044A-4B95-B1EE-2EB881005CEDQ37259586-BDB9630C-CECB-4E1A-950F-43497033A2E2Q37310612-46C88611-4DA3-4D49-A294-72F0429EBCCDQ37340462-69E01496-AC28-4910-B3A4-93DE1910B1E6Q37402451-31D66553-7793-4695-89C0-FDE134198897Q37412334-B7C1E69F-F32B-4C02-A05E-9C23BFBE6EA0Q37448957-89EB9448-4F72-451A-8D7D-C0DC2CAFCD1BQ37513871-A8701E02-E771-4496-A9B2-02CE8D5A64F7Q37547268-068EC186-0D09-4CBD-9B38-F27EE3F8ABA8Q37640613-1C77727E-0D0F-4832-96D9-909A4653AC5EQ37735454-5D2B87F0-E689-4AB6-BE8E-D0DFF689341DQ37744997-B415F905-2C0B-4DCB-BA04-59F39107BD07Q37769017-43600749-F640-46FD-B567-2AE1EE1B38B2Q37908142-FD13116B-AC35-4025-A5A0-BCE301C82CCBQ37952804-692D220A-6B6B-47CE-960D-B7FA537BC041Q38031384-9A013AD0-0452-4845-9A5C-6F6CF890FE50Q38095583-E64CCD50-F40A-42CF-9AB2-9F02A739DB09Q38164258-B9F6540D-CA82-4669-9801-1C1EE91D8CE3
P2860
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients
description
im Oktober 2005 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 2005
@uk
name
A phase II trial of vaccinatio ...... n metastatic melanoma patients
@en
A phase II trial of vaccinatio ...... n metastatic melanoma patients
@nl
type
label
A phase II trial of vaccinatio ...... n metastatic melanoma patients
@en
A phase II trial of vaccinatio ...... n metastatic melanoma patients
@nl
prefLabel
A phase II trial of vaccinatio ...... n metastatic melanoma patients
@en
A phase II trial of vaccinatio ...... n metastatic melanoma patients
@nl
P2093
P50
P1476
A phase II trial of vaccinatio ...... n metastatic melanoma patients
@en
P2093
Adriano Piris
Agata Cova
Annabella Di Florio
Cristina Santantonio
Daisuke Nonaka
Diego Tosi
Elda Lamaj
Elisabetta Pennacchioli
Flavio Arienti
P2860
P2888
P304
P356
10.1007/S00262-005-0084-8
P50
P577
2005-10-08T00:00:00Z